On May 22, 2024 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, reported its participation in multiple investor conferences in June 2024 (Press release, Adagene, MAY 22, 2024, View Source [SID1234643526]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide a company update, including progress on the masked, anti-CTLA-4 SAFEbody ADG126. Company management will also host investor meetings.

Jefferies Global Healthcare Conference 2024

Date: Wednesday, June 5
Time: 4:30-4:55 PM (Eastern Time)
Location: New York City
Goldman Sachs 45th Annual Global Healthcare Conference

Date: Thursday, June 13
Time: 10:00-10:35 AM (Eastern Time)
Location: Miami
HC Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Date: Tuesday, June 25
Time: TBD for presentation
Location: Virtual
A live webcast of the relevant presentations will also be accessible in the Investors section of the company’s website at View Source A webcast replay will be available for at least 30 days.